Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $27.00 by Analysts at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective decreased by HC Wainwright from $28.00 to $27.00 in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also commented on ENTA. StockNews.com lowered shares of Enanta Pharmaceuticals from a hold rating to a sell rating in a report on Saturday, April 6th. JPMorgan Chase & Co. dropped their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating on the stock in a research note on Thursday, February 8th. Finally, JMP Securities reduced their price objective on Enanta Pharmaceuticals from $23.00 to $22.00 and set a market outperform rating for the company in a research report on Tuesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Hold and a consensus target price of $19.00.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock opened at $13.10 on Tuesday. Enanta Pharmaceuticals has a 1 year low of $8.08 and a 1 year high of $36.04. The company has a market capitalization of $277.20 million, a P/E ratio of -2.00 and a beta of 0.54. The business has a 50-day moving average of $14.91 and a two-hundred day moving average of $12.08.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. On average, equities analysts anticipate that Enanta Pharmaceuticals will post -4.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of ENTA. Nisa Investment Advisors LLC raised its holdings in Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,281 shares in the last quarter. Clearstead Advisors LLC bought a new position in Enanta Pharmaceuticals in the third quarter valued at approximately $57,000. Quantbot Technologies LP grew its stake in Enanta Pharmaceuticals by 2,300.0% in the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,900 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in Enanta Pharmaceuticals in the third quarter valued at approximately $113,000. Finally, Laurion Capital Management LP bought a new position in Enanta Pharmaceuticals in the third quarter valued at approximately $126,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.